Valeo Financial Advisors LLC Has $2.18 Million Stock Holdings in Boston Scientific Corporation (NYSE:BSX)

Valeo Financial Advisors LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 17.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 21,621 shares of the medical equipment provider's stock after buying an additional 3,144 shares during the period. Valeo Financial Advisors LLC's holdings in Boston Scientific were worth $2,180,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Highview Capital Management LLC DE grew its stake in Boston Scientific by 4.0% in the 1st quarter. Highview Capital Management LLC DE now owns 25,491 shares of the medical equipment provider's stock valued at $2,572,000 after buying an additional 984 shares during the last quarter. Ninety One UK Ltd boosted its holdings in Boston Scientific by 6.4% in the 1st quarter. Ninety One UK Ltd now owns 3,855,804 shares of the medical equipment provider's stock valued at $388,974,000 after purchasing an additional 232,997 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Boston Scientific by 40.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 18,437 shares of the medical equipment provider's stock valued at $1,860,000 after purchasing an additional 5,294 shares during the period. Capital Management Associates Inc boosted its holdings in Boston Scientific by 100.0% in the 1st quarter. Capital Management Associates Inc now owns 31,308 shares of the medical equipment provider's stock valued at $3,158,000 after purchasing an additional 15,654 shares during the period. Finally, Interchange Capital Partners LLC bought a new stake in Boston Scientific in the 1st quarter valued at about $232,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BSX. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Needham & Company LLC reaffirmed a "buy" rating and set a $115.00 price target on shares of Boston Scientific in a report on Wednesday, May 28th. Robert W. Baird upped their price target on shares of Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Finally, Evercore ISI upped their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Twenty-two research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $116.09.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $106.97, for a total transaction of $5,348,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $19,077,243.74. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the sale, the chief executive officer owned 1,476,882 shares of the company's stock, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 461,970 shares of company stock valued at $47,755,193 over the last 90 days. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Down 1.3%

Shares of NYSE BSX opened at $102.44 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. Boston Scientific Corporation has a 52-week low of $71.88 and a 52-week high of $107.53. The firm has a 50 day moving average price of $103.45 and a two-hundred day moving average price of $100.33. The stock has a market cap of $151.55 billion, a P/E ratio of 74.77, a price-to-earnings-growth ratio of 2.70 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The company had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same period in the prior year, the company posted $0.56 earnings per share. Boston Scientific's revenue for the quarter was up 20.9% compared to the same quarter last year. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.